Pacific Biosciences of California, Inc.
NASDAQ:PACBMedical - Devices
+$0.04 today
- Market cap
- $571.39M
- Beta
- 2.32
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.42
Volume 15.30M
Average 6.06M
PACB Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Pacific Biosciences of California, Inc.NASDAQ: PACB
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 97.4% from a year ago
Total equity stood at $2.37M at the end of Q1 FY2026, down 97.4% from a year earlier and down 55.8% from the prior quarter. Over 3 fiscal years it compounded at -78.8% a year.
Context
- Total equity amounted to 0.3% of total assets at the end of Q1 FY2026, down 10.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -97.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 5.35M USD
- Year-over-year change
- -98.9%
- 4-year CAGR
- -71.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.35M | -98.9% |
| FY2024 | 2024-12-31 | 506.59M | -27.8% |
| FY2023 | 2023-12-31 | 701.3M | +24.6% |
| FY2022 | 2022-12-31 | 562.9M | -28.8% |
| FY2021 | 2021-12-31 | 790.99M | — |
Total Equity vs competitors
How PACB compares with its peers on the latest reported figures
- PACB's Mar 2026 total equity of $2.37M is the lowest of the 3 companies compared; the peer median is $1.52B.
- Its year-over-year change of -97.4% is the lowest of 3, against a peer median of +3.5%.
- Total equity amounts to 0.3% of total assets for PACB, versus a peer median of 68.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.84B | +25.7% | -25.6% | 42.7% | |
| Mar 2026 | $200.74M | -18.7% | -15.0% | 94.1% | |
| Mar 2026 | $2.37M | -97.4% | -78.8% | 0.3% | |
| Peer median (excluding PACB) | $1.52B | +3.5% | -20.3% | 68.4% | |
Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 460.73M | 325.09M | 179.91M | 55.37M | 63.71M |
| Short-term Investments | 583.68M | 447.23M | 451.51M | 334.56M | 215.8M |
| Net Receivables | 24.24M | 18.79M | 36.62M | 27.52M | 35.45M |
| Inventory | 24.6M | 50.38M | 56.68M | 58.76M | 49.29M |
| Other Current Assets | 500K | 300K | 17.34M | 19.47M | 10.79M |
| Total Current Assets | 1.1B | 852.07M | 742.05M | 495.68M | 375.03M |
| Property, Plant & Equipment (Net) | 79.12M | 81.34M | 69.03M | 46.6M | 65.84M |
| Goodwill | 409.97M | 409.97M | 462.26M | 317.76M | 317.76M |
| Intangible Assets | 410.98M | 410.25M | 456.98M | 389.57M | 15.12M |
| Long-term Investments | 0 | 0 | 0 | 0 | 1.53M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 5.76M | 13.45M | 15.7M | 10.84M | 8.79M |
| Total Non-current Assets | 905.84M | 915.01M | 1B | 764.77M | 409.05M |
| Total Assets | 2.01B | 1.77B | 1.75B | 1.26B | 784.08M |
| Account Payables | 11M | 12.03M | 15.06M | 16.59M | 20.77M |
| Short-term Debt | 1.61M | 1.84M | 490K | 0 | 448K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 10.98M | 30.5M | 16.34M | 13.86M | 0 |
| Other Current Liabilities | 4.15M | 175.5M | 7.84M | 3.22M | 32.75M |
| Total Current Liabilities | 71.71M | 263.34M | 95.03M | 66.3M | 54.42M |
| Long-term Debt | 896.07M | 896.68M | 892.24M | 647.49M | 702.42M |
| Deferred Tax Liabilities | (25.05M) | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 25.05M | 1.79M | 5.53M | 5.9M | 19.87M |
| Other Non-current Liabilities | 198.24M | 1.3M | 20.3M | 19.25M | (55.01M) |
| Total Non-current Liabilities | 1.14B | 940.85M | 949.68M | 687.55M | 724.32M |
| Total Liabilities | 1.22B | 1.2B | 1.04B | 753.85M | 778.73M |
| Common Stock | 221K | 227K | 268K | 294K | 302K |
| Retained Earnings | (1.22B) | (1.53B) | (1.84B) | (2.15B) | (2.7B) |
| Accumulated OCI | (1.09M) | (4.77M) | 219K | 422K | 457K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 790.99M | 562.9M | 701.3M | 506.59M | 5.35M |
| Total Debt | 955.36M | 948.48M | 933.93M | 672.43M | 759.46M |
| Net Debt | 494.63M | 623.39M | 754.02M | 617.06M | 695.76M |
Pacific Biosciences of California, Inc.
NASDAQ:PACB
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.